SEC Comment Letter for PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) (PLSE) — Apr 18, 2016
PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)
Date: April 18, 2016 · CIK: 0001625101 · Accession: 0000000000-16-072508
AI Filing Summary & Sentiment
Show Raw Text
Mail Stop 3030
April 15, 2016
Via E -mail
Darrin R. Uecker
President and Chief Executive Officer
Pulse Biosciences, Inc.
849 Mitten Road, Suite 104
Burlingame, California 94010
Re: Pulse Biosciences, Inc.
Amendment No. 2 to Registration Statement on Form S -1
Filed March 28, 2016
File No. 333 -208694
Dear Mr. Uecker :
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information . If you do not believe our comments apply t o your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have a dditional comments. Unless we note
otherwise, our references to prior comments are to comments in our March 21, 2016 letter.
Prospectus Summary, page 1
1. We are unable to agree with your response to prior comment 5 given the tests appear to
be in order to pursue regulatory clearance for your system rather than for marketing.
Please revise your disclosure to highlight the limited nature of certain of the referenced
studies and trials.
Business, page 26
2. Please tell us why you do include in this section disclosure required by Item 101(a) of
Regulation S -K regarding your relationship with Electroblate, Inc.
Darrin R. Uecker
Pulse Biosciences, Inc.
April 15, 2016
Page 2
Exhibit s
3. We are unable to agree with your response to prior comment 13 given the agreement was
performed in part after you filed the registration statement on December 22, 2015. File
as an exhibit the research and funding agreement mentioned on page 40.
Exhibit 5.1
4. The opinion that you file to satisfy your obligations under Regulation S -K Item 60 1(b)(5)
may not assume conclusions of law that are a necessary requirement of the ultimate
opinion nor may it assume any of the material facts underlying the opinion or facts that
are readily ascertainable. We note the last two sentences of the second para graph of the
exhibit that you filed. Please file an opinion that is revised as appropriate.
You may contact David Burton at (202) 551 -3640 or Kevin Kuhar, Accounting Branch
Chief, at (202) 551 -3662 if you have questions regarding comments on the financi al statements
and related matters. Please contact Tom Jones at (202) 551 -3602 or me at (202) 551 -3528 with
any other questions.
Sincerely,
/s/ Amanda Ravitz
Amanda Ravitz
Assistant Director
Office of Electronics and Machinery
cc: Andrew Hudders, Esq.